BridgeBio Pharma Inc
BBIO61.370USD
-0.610-0.98%
收盘 11/04, 16:00（美东）报价延迟15分钟
11.82B总市值
亏损市盈率 TTM
关于 BridgeBio Pharma Inc 公司
BridgeBio Pharma, Inc. 是一家商业阶段的生物制药公司。该公司专注于发现、创造、测试和提供变革性药物，以治疗患有具有明确遗传驱动因素的遗传疾病和癌症的患者。该公司的开发项目范围从早期科学到高级临床试验，包括用于治疗淀粉样变性 TTR (ATTR) 的下一代小分子近乎完全的转甲状腺素蛋白 (TTR) 稳定剂 Acoramidis (AG10)；低剂量 infigratinib，一种口服 FGFR1-3 选择性酪氨酸激酶抑制剂 (TKI)，作为软骨发育不全儿童的治疗选择； Encaleret 是一种钙敏感受体（CaSR）小分子拮抗剂，用于治疗 1 型常染色体显性低钙血症（ADH1）；BBP-418 是一种在研的口服小分子底物补充疗法，该公司正在开发用于治疗 LGMD2I（也称为 LGMDR9）。
BridgeBio Pharma Inc简介
公司代码BBIO
公司名称BridgeBio Pharma Inc
上市日期Jun 27, 2019
CEODr. Neil Kumar, Ph.D.
员工数量725
证券类型Ordinary Share
年结日Jun 27
公司地址3160 Porter Dr.
城市PALO ALTO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94304
电话16503919740
网址https://bridgebio.com/
公司代码BBIO
上市日期Jun 27, 2019
CEODr. Neil Kumar, Ph.D.
BridgeBio Pharma Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Neil Kumar, Ph.D.
Dr. Neil Kumar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
6.17M
+0.09%
Dr. Charles J. Homcy, M.D.
Dr. Charles J. Homcy, M.D.
Lead Director, Chairman of Pharmaceuticals
Lead Director, Chairman of Pharmaceuticals
916.67K
-24.66%
Mr. Ali J. Satvat
Mr. Ali J. Satvat
Independent Director
Independent Director
165.99K
+4.13%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
95.08K
+7.45%
Dr. Thomas Trimarchi, Ph.D.
Dr. Thomas Trimarchi, Ph.D.
President, Chief Financial Officer
President, Chief Financial Officer
57.85K
-26.92%
Mr. Fred Hassan
Mr. Fred Hassan
Lead Independent Director
Lead Independent Director
25.89K
+34.14%
Mr. Ronald J. Daniels, J.D.
Mr. Ronald J. Daniels, J.D.
Independent Director
Independent Director
16.99K
+63.34%
Dr. Randal W. (Randy) Scott, Ph.D.
Dr. Randal W. (Randy) Scott, Ph.D.
Independent Director
Independent Director
15.59K
+73.21%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
13.74K
+92.13%
Dr. Eric Aguiar, M.D.
Dr. Eric Aguiar, M.D.
Independent Director
Independent Director
6.59K
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Neil Kumar, Ph.D.
Dr. Neil Kumar, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
6.17M
+0.09%
Dr. Charles J. Homcy, M.D.
Dr. Charles J. Homcy, M.D.
Lead Director, Chairman of Pharmaceuticals
Lead Director, Chairman of Pharmaceuticals
916.67K
-24.66%
Mr. Ali J. Satvat
Mr. Ali J. Satvat
Independent Director
Independent Director
165.99K
+4.13%
Mr. James C. (Jim) Momtazee
Mr. James C. (Jim) Momtazee
Independent Director
Independent Director
95.08K
+7.45%
Dr. Thomas Trimarchi, Ph.D.
Dr. Thomas Trimarchi, Ph.D.
President, Chief Financial Officer
President, Chief Financial Officer
57.85K
-26.92%
Mr. Fred Hassan
Mr. Fred Hassan
Lead Independent Director
Lead Independent Director
25.89K
+34.14%
收入明细
单位: USD更新时间: 10月6日 周一
单位: USD更新时间: 10月6日 周一
FY2025Q2
FY2025Q1
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
暂无数据
地区USD
名称
营收
占比
United States
71.53M
64.70%
Europe Middle East and Africa (EMEA)
35.05M
31.70%
Asia Pacific (APAC)
3.98M
3.60%
业务
地区
暂无数据
股东统计
更新时间: 10月24日 周五
更新时间: 10月24日 周五
持股股东
股东类型
持股股东
持股股东
占比
Viking Global Investors LP
9.23%
The Vanguard Group, Inc.
8.54%
Kohlberg Kravis Roberts & Co. L.P.
6.88%
BlackRock Institutional Trust Company, N.A.
6.17%
Janus Henderson Investors
4.81%
其他
64.37%
持股股东
持股股东
占比
Viking Global Investors LP
9.23%
The Vanguard Group, Inc.
8.54%
Kohlberg Kravis Roberts & Co. L.P.
6.88%
BlackRock Institutional Trust Company, N.A.
6.17%
Janus Henderson Investors
4.81%
其他
64.37%
股东类型
持股股东
占比
Investment Advisor
34.43%
Investment Advisor/Hedge Fund
33.14%
Hedge Fund
16.85%
Private Equity
8.85%
Individual Investor
4.72%
Research Firm
3.21%
Venture Capital
1.96%
Sovereign Wealth Fund
1.02%
Bank and Trust
0.60%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
653
194.03M
100.69%
-638.66K
2025Q2
626
190.36M
99.64%
-5.40M
2025Q1
628
200.01M
105.33%
-2.20M
2024Q4
586
190.11M
100.07%
-10.58M
2024Q3
566
185.43M
98.60%
-19.02M
2024Q2
541
188.12M
100.51%
-8.17M
2024Q1
529
185.29M
101.24%
-2.60M
2023Q4
525
179.04M
102.35%
-7.24M
2023Q3
519
174.99M
102.35%
-1.47M
2023Q2
503
162.75M
101.40%
-17.06M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Viking Global Investors LP
17.78M
9.3%
-822.74K
-4.42%
Aug 14, 2025
The Vanguard Group, Inc.
16.45M
8.61%
+1.58M
+10.64%
Jun 30, 2025
Kohlberg Kravis Roberts & Co. L.P.
13.26M
6.94%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.89M
6.22%
+714.59K
+6.39%
Jun 30, 2025
Janus Henderson Investors
9.28M
4.85%
+2.11M
+29.35%
Jun 30, 2025
Farallon Capital Management, L.L.C.
7.90M
4.13%
+2.17M
+37.85%
Jun 30, 2025
Kumar (Neil)
6.17M
3.23%
+5.69K
+0.09%
Aug 20, 2025
Aisling Capital Management LP
6.07M
3.17%
--
--
Jun 30, 2025
State Street Investment Management (US)
5.90M
3.08%
+146.98K
+2.56%
Jun 30, 2025
Two Sigma Investments, LP
4.02M
2.1%
+2.91M
+260.34%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
Tema Oncology ETF
5.03%
Franklin Genomic Advancements ETF
3.3%
Tema Heart & Health ETF
2.96%
Invesco Dorsey Wright Healthcare Momentum ETF
2.33%
Virtus LifeSci Biotech Products ETF
2.18%
SPDR S&P Biotech ETF
2.03%
Direxion Daily S&P Biotech Bull 3X Shares
1.16%
ProShares Ultra Nasdaq Biotechnology
1.03%
Federated Hermes MDT Small Cap Core ETF
1.03%
Invesco Nasdaq Biotechnology ETF
1%
查看更多
Tema Oncology ETF
占比5.03%
Franklin Genomic Advancements ETF
占比3.3%
Tema Heart & Health ETF
占比2.96%
Invesco Dorsey Wright Healthcare Momentum ETF
占比2.33%
Virtus LifeSci Biotech Products ETF
占比2.18%
SPDR S&P Biotech ETF
占比2.03%
Direxion Daily S&P Biotech Bull 3X Shares
占比1.16%
ProShares Ultra Nasdaq Biotechnology
占比1.03%
Federated Hermes MDT Small Cap Core ETF
占比1.03%
Invesco Nasdaq Biotechnology ETF
占比1%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
